Phase-3 SunRISe-2: TAR-200 Plus Cetrelimab Versus Chemoradiotherapy in Muscle-Invasive Bladder Cancer

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Patient Partners in NSCLC: Collaborating to Enhance Quality of Life and Outcomes With EGFRi-Associated Dermatologic Toxicities
Patient Partners in NSCLC: Collaborating to Enhance Quality of Life and Outcomes With EGFRi-Associated Dermatologic Toxicities
CME/CE
Patient Partners in NSCLC: Collaborating to Enhance Quality of Life and Outcomes With EGFRi-Associated Dermatologic Toxicities
0.25 credits
- Jonathan Leventhal, MD
- Shahnaz Singh-Kandah, NP
0.25 credits
MinuteCE®
Innovations in Oncology Learning Center: From Guidelines to Practice—Breast Cancer
1.50 credits 10 episodes
- William J. Gradishar, MD
- Erica L. Mayer, MD, MPH
- Peter Schmid, FRCP, MD, PhD
1.50 credits 10 episodes
Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC
Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC
MinuteCE®
Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC
1.50 program credits
- Peter Schmid, FRCP, MD, PhD
1.50 program credits
First-Line Advanced Gastric Cancer: Best Practices for Biomarker-Directed Treatment Approaches—A Case Study
First-Line Advanced Gastric Cancer: Best Practices for Biomarker-Directed Treatment Approaches—A Case Study
MinuteCE®
First-Line Advanced Gastric Cancer: Best Practices for Biomarker-Directed Treatment Approaches—A Case Study
1.25 program credits
- Sara Lonardi, MD
1.25 program credits

Phase-3 SunRISe-2: TAR-200 Plus Cetrelimab Versus Chemoradiotherapy in Muscle-Invasive Bladder Cancer

Recommended

Title

Share on ReachMD